Evoke Pharma Inc (NASDAQ:EVOK)

6.43
Data as of 3:17pm ET
 -0.074 / -1.14%
Today’s Change
4.72
Today|||52-Week Range
11.40
+8.98%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$38.9M

Company Description

Evoke Pharma, Inc. operates as a pharmaceutical company, which focuses on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. It develops EVK-001a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matt J. D'Onofrio, Cam L. Garner, Scott L. Glenn and David A. Gonyer on January 29, 2007 and is headquartered in San Diego, CA.

Contact Information

Evoke Pharma, Inc.
505 Lomas Santa Fe Drive
Solana Beach California 92075
P:(858) 345-1494
Investor Relations:

Employees

Shareholders

Individual stakeholders56.25%
Other institutional4.53%
Mutual fund holders2.22%

Top Executives

David A. GonyerPresident, Chief Executive Officer & Director
Marilyn R. CarlsonChief Medical Officer
Matthew J. D'OnofrioSecretary, Treasurer, Chief Business Officer & EVP

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.